PURPOSE: To compare the geographical differences in the prevalence of chronic polypharmacy in community-dwelling older people over 11 years. METHODS: This study analyzed nearly two million patients aged 65-94 years recorded in the Drug Administrative Database of the Lombardy Region (Northern Italy) from 2000 to 2010. Chronic polypharmacy was defined as taking five or more drugs in 1 month for at least 6 months (consecutive or not) in a year. RESULTS: There was a significant spatial autocorrelation that increased at the municipality level from 2000 (Moran's I Index = 0.26, z score = 16.91, p < 0.0001) to 2010 (Moran's I Index = 0.36, z score = 23.78, p < 0.0001). Clusters of high (Z(G) > 1.96) and low (Z(G) < -1.96) prevalence rates of chronic polypharmacy were found and were not influenced by age. Chronic polypharmacy weakly correlated with hospital admission (2000: ρ = 0.08, p = 0.0032; 2005: ρ = 0.11, p < 0.0001; 2010: ρ = 0.18, p < 0.0001), but not with mortality. CONCLUSIONS: There were geographical differences in the prevalence of older people with chronic polypharmacy that were only partly explained by health indicators. Targeted activities on prescription practice to ensure that the prescribing of chronic polypharmacy is appropriate are required.
PURPOSE: To compare the geographical differences in the prevalence of chronic polypharmacy in community-dwelling older people over 11 years. METHODS: This study analyzed nearly two million patients aged 65-94 years recorded in the Drug Administrative Database of the Lombardy Region (Northern Italy) from 2000 to 2010. Chronic polypharmacy was defined as taking five or more drugs in 1 month for at least 6 months (consecutive or not) in a year. RESULTS: There was a significant spatial autocorrelation that increased at the municipality level from 2000 (Moran's I Index = 0.26, z score = 16.91, p < 0.0001) to 2010 (Moran's I Index = 0.36, z score = 23.78, p < 0.0001). Clusters of high (Z(G) > 1.96) and low (Z(G) < -1.96) prevalence rates of chronic polypharmacy were found and were not influenced by age. Chronic polypharmacy weakly correlated with hospital admission (2000: ρ = 0.08, p = 0.0032; 2005: ρ = 0.11, p < 0.0001; 2010: ρ = 0.18, p < 0.0001), but not with mortality. CONCLUSIONS: There were geographical differences in the prevalence of older people with chronic polypharmacy that were only partly explained by health indicators. Targeted activities on prescription practice to ensure that the prescribing of chronic polypharmacy is appropriate are required.
Authors: C Franchi; M Sequi; M Bonati; A Nobili; L Pasina; A Bortolotti; I Fortino; L Merlino; A Clavenna Journal: Infection Date: 2011-06-25 Impact factor: 3.553
Authors: Danijela Gnjidic; Sarah N Hilmer; Fiona M Blyth; Vasi Naganathan; Louise Waite; Markus J Seibel; Andrew J McLachlan; Robert G Cumming; David J Handelsman; David G Le Couteur Journal: J Clin Epidemiol Date: 2012-06-27 Impact factor: 6.437
Authors: Dima M Qato; G Caleb Alexander; Rena M Conti; Michael Johnson; Phil Schumm; Stacy Tessler Lindau Journal: JAMA Date: 2008-12-24 Impact factor: 56.272
Authors: Xue Feng; Xi Tan; Brittany Riley; Tianyu Zheng; Thomas K Bias; James B Becker; Usha Sambamoorthi Journal: Ann Pharmacother Date: 2017-06-21 Impact factor: 3.154
Authors: Henrike Galenkamp; Dorly J H Deeg; Renate T de Jongh; Jan W P F Kardaun; Martijn Huisman Journal: BMJ Open Date: 2016-08-16 Impact factor: 2.692